A recalled pill hid a stimulant dose linked to heart attacks and death

SUPPLX.com, an online retailer based in Grant-Valkaria, Florida, has recalled two supplements sold nationwide for male sexual enhancement after laboratory testing turned up a stimulant that never appeared on either label. Federal regulators confirmed that Business Pill and Branch Manager for Men both contained yohimbine at levels described as dangerously high. The recall, announced September 3, 2026, covers every lot distributed since September 16, 2023, meaning the affected capsules sat on shelves and in online carts for nearly three years before anyone pulled them.

Yohimbine can trigger severe high blood pressure, a racing heartbeat, and in the worst cases cardiac arrhythmia or a heart attack. The recall notice states plainly that death has been reported in cases of severe overdose. The danger compounds for anyone already using a stimulant such as caffeine or an ephedra-based product, an ADHD medication, or certain antidepressants — interactions nobody buying a bottle labeled only as a dietary supplement would have any reason to expect.

Why an unlabeled dose of yohimbine turns dangerous

Yohimbine comes from the bark of Pausinystalia yohimbe, an evergreen tree native to central and western Africa long used as a folk aphrodisiac. The National Center for Complementary and Integrative Health says the compound has been tied to cardiac arrhythmia, blood pressure problems, heart attacks and seizures even in supplement doses that manufacturers present as ordinary. It was also once formulated into a prescription drug for erectile dysfunction before safer, more effective treatments largely replaced it, and the agency notes it remains illegal in the United States to sell an over-the-counter product containing yohimbine as an impotence treatment without separate FDA approval.

The FDA’s recall announcement lists a longer chain of symptoms tied to the doses found in these two products: severe gastrointestinal distress, including nausea, vomiting, diarrhea and stomach pain, plus acute neurologic and psychiatric effects such as anxiety, insomnia, mania, drowsiness, disorientation, tremors and seizures. In people with schizophrenia, the notice adds, yohimbine can trigger psychosis. None of that risk profile appeared on packaging that instead promised, in the product’s own marketing language, to make a man’s business harder, larger and longer.

A federal warning that came three months before the recall

The September recall was not the government’s first move against these two products. On June 10, 2026, the FDA issued a notice advising consumers not to purchase or use Branch Manager for Men, and a matching notice the same day flagged Business Pill for the identical undeclared ingredient. Both warnings ran nearly three months before SUPPLX.com’s voluntary recall, and during that gap the products remained available for purchase through the company’s own website.

The recalled products were packaged as single capsules in blister cards sold inside 24-count retail boxes, with lot and expiration information printed on the back of each card — in the upper-right corner on Business Pill, directly above the barcode on Branch Manager for Men. The recall applies to every lot and best-by date distributed between September 16, 2023, and June 11, 2026, and the company says it is notifying affected customers directly rather than relying solely on the public notice.

The regulatory gap that let it happen

Dietary supplements occupy a different legal category than drugs, and that distinction sits at the center of how products like these reach consumers at all. Manufacturers and distributors are responsible for evaluating a supplement’s safety and labeling before it goes to market, and the FDA does not pre-approve a supplement the way it would a new prescription drug. The agency’s own consumer guidance acknowledges it cannot test every product sold under the supplement label, which leaves the job of catching a hidden ingredient to after-the-fact laboratory analysis, adverse-event reports, or, in this case, both arriving months apart.

That gap is part of why yohimbine keeps resurfacing in recalled sexual-enhancement products years after its risks were first documented in the medical literature. NCCIH’s safety guidance also notes that supplements labeled as containing yohimbe frequently misstate, or omit entirely, how much yohimbine they actually contain, which means a buyer reading the label has no reliable way to judge the dose sitting in the capsule.

What buyers of the pills should do now

Anyone who still has Business Pill or Branch Manager for Men is advised to stop taking it immediately and dispose of the remaining product, according to the recall notice. Consumers who have experienced symptoms that might be related to either product are urged to contact a physician, and adverse events can be reported directly to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program online or by fax.

SUPPLX.com is fielding consumer questions through a dedicated recall phone line and email address rather than a named company spokesperson, and the FDA notice does not identify an individual investigator behind the laboratory findings. It is a reminder that a recall like this one is driven by chemical analysis rather than a public-facing face, even after two products carrying an undisclosed, dangerous dose sat on the market for the better part of three years.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview